129 related articles for article (PubMed ID: 35788294)
21. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K
Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients.
Carmon L; Avivi I; Kovjazin R; Zuckerman T; Dray L; Gatt ME; Or R; Shapira MY
Br J Haematol; 2015 Apr; 169(1):44-56. PubMed ID: 25496030
[TBL] [Abstract][Full Text] [Related]
23. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
Kovjazin R; Volovitz I; Kundel Y; Rosenbaum E; Medalia G; Horn G; Smorodinsky NI; Brenner B; Carmon L
Vaccine; 2011 Jun; 29(29-30):4676-86. PubMed ID: 21570434
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit.
Lu W; Qiu L; Yan Z; Lin Z; Cao M; Hu C; Wang Z; Wang J; Yu Y; Cheng X; Cao P; Li R
Oncotarget; 2015 Oct; 6(33):34537-48. PubMed ID: 26417929
[TBL] [Abstract][Full Text] [Related]
25. Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope.
Heukamp LC; van Hall T; Ossendorp F; Burchell JM; Melief CJ; Taylor-Papadimitriou J; Offringa R
J Immunother; 2002; 25(1):46-56. PubMed ID: 11926165
[TBL] [Abstract][Full Text] [Related]
26. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
[TBL] [Abstract][Full Text] [Related]
27. Cellular and humoral immunogenicity of hamster polyomavirus-derived virus-like particles harboring a mucin 1 cytotoxic T-cell epitope.
Dorn DC; Lawatscheck R; Zvirbliene A; Aleksaite E; Pecher G; Sasnauskas K; Ozel M; Raftery M; Schönrich G; Ulrich RG; Gedvilaite A
Viral Immunol; 2008 Mar; 21(1):12-27. PubMed ID: 18355119
[TBL] [Abstract][Full Text] [Related]
28. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
[TBL] [Abstract][Full Text] [Related]
29. ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen.
Carrell RK; Stanton RA; Ethier SP; LaRue AC; Soloff AC
Vaccine; 2018 Oct; 36(42):6262-6269. PubMed ID: 30219366
[TBL] [Abstract][Full Text] [Related]
30. Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1.
Correa I; Plunkett T; Coleman J; Galani E; Windmill E; Burchell JM; Taylor-Papdimitriou J
Int J Cancer; 2005 Jul; 115(5):760-8. PubMed ID: 15729696
[TBL] [Abstract][Full Text] [Related]
31. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.
Ryan SO; Vlad AM; Islam K; Gariépy J; Finn OJ
Biol Chem; 2009 Jul; 390(7):611-8. PubMed ID: 19426130
[TBL] [Abstract][Full Text] [Related]
32. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
33. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
[TBL] [Abstract][Full Text] [Related]
34. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
[TBL] [Abstract][Full Text] [Related]
35. The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours.
Yang H; Cho NH; Seong SY
Clin Exp Immunol; 2009 Nov; 158(2):174-85. PubMed ID: 19737144
[TBL] [Abstract][Full Text] [Related]
36. Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice.
Curry JM; Besmer DM; Erick TK; Steuerwald N; Das Roy L; Grover P; Rao S; Nath S; Ferrier JW; Reid RW; Mukherjee P
PLoS One; 2019; 14(11):e0224309. PubMed ID: 31693710
[TBL] [Abstract][Full Text] [Related]
37. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.
Tsang KY; Palena C; Gulley J; Arlen P; Schlom J
Clin Cancer Res; 2004 Mar; 10(6):2139-49. PubMed ID: 15041735
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
39. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; Livingston PO; Hilgers J; Kenemans P
Int J Cancer; 2001 Jul; 93(1):97-106. PubMed ID: 11391628
[TBL] [Abstract][Full Text] [Related]
40. Humanization and epitope mapping of the H23 anti-MUC1 monoclonal antibody reveals a dual epitope specificity.
Mazor Y; Keydar I; Benhar I
Mol Immunol; 2005 Jan; 42(1):55-69. PubMed ID: 15488944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
